We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+23.45%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.68B
AUM Growth
+$331M
Cap. Flow
+$76.5M
Cap. Flow %
4.56%
Top 10 Hldgs %
63.28%
Holding
89
New
21
Increased
18
Reduced
12
Closed
21

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$44.6M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$15.9M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$12.3M
4
AMGN icon
Amgen
AMGN
+$12.2M
5
MGNX icon
MacroGenics
MGNX
+$10.6M

Top Sells

Rank Stock Value
1
NXTC icon
NextCure
NXTC
+$23.5M
2
MRK icon
Merck
MRK
+$15.8M
3
LLY icon
Eli Lilly
LLY
+$15.8M
4
INSM icon
Insmed
INSM
+$11.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.46M

Sector Composition

Rank Sector Weight
1 Healthcare 91.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
26
Regenxbio
RGNX
$622M
$12.3M 0.73%
271,114
+211,607
+356% +$7.39M
GWPH
27
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$11.6M 0.69%
100,762
+17,818
+21% +$2M
CYTK icon
28
Cytokinetics
CYTK
$10.9B
$10.6M 0.63%
508,394
+159,098
+46% +$2.91M
MGNX icon
29
MacroGenics
MGNX
$254M
$10.5M 0.62%
+458,807
New +$10.6M
TCRR
30
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$10.3M 0.61%
333,707
+160,679
+93% +$4.06M
INSM icon
31
Insmed
INSM
$22.7B
$10.3M 0.61%
309,662
-305,481
-50% -$11.2M
OBSV
32
DELISTED
ObsEva SA Ordinary Shares
OBSV
$9.88M 0.59%
4,749,623
– –
ARNA
33
DELISTED
Arena Pharmaceuticals Inc
ARNA
$9.32M 0.56%
121,373
+33,223
+38% +$2.49M
SRPT icon
34
Sarepta Therapeutics
SRPT
$1.68B
$8.84M 0.53%
+51,848
New +$7.68M
ACAD icon
35
Acadia Pharmaceuticals
ACAD
$4.35B
$8.8M 0.52%
164,625
+115,629
+236% +$5.74M
BCRX icon
36
BioCryst Pharmaceuticals
BCRX
$2.43B
$8.37M 0.5%
1,122,800
+329,746
+42% +$1.7M
SNDX icon
37
Syndax Pharmaceuticals
SNDX
$1.82B
$8.29M 0.49%
+372,909
New +$7.73M
MIRM icon
38
Mirum Pharmaceuticals
MIRM
$6.96B
$7.94M 0.47%
454,974
+133,722
+42% +$2.63M
CHRS icon
39
Coherus Oncology
CHRS
$225M
$7.55M 0.45%
434,555
– –
CCXI
40
DELISTED
ChemoCentryx, Inc.
CCXI
$7.01M 0.42%
113,213
+31,978
+39% +$1.83M
JNCE
41
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$6.48M 0.39%
+925,280
New +$7.2M
PBYI icon
42
Puma Biotechnology
PBYI
$407M
$6.46M 0.38%
629,650
+153,668
+32% +$1.56M
LLY icon
43
Eli Lilly
LLY
$1.07T
$6.23M 0.37%
36,909
-105,523
-74% -$15.8M
AMRN
44
Amarin Corp
AMRN
$290M
$5.72M 0.34%
58,529
– –
ALGS icon
45
Aligos Therapeutics
ALGS
$25.2M
$5.28M 0.31%
+7,642
New +$3.72M
RCUS icon
46
Arcus Biosciences
RCUS
$3.5B
$4.84M 0.29%
+186,278
New +$4.51M
XLRN
47
DELISTED
Acceleron Pharma
XLRN
$4.69M 0.28%
36,688
-22,858
-38% -$2.68M
IOVA icon
48
PUT
Iovance Biotherapeutics
IOVA
$2.19B
$4.64M 0.28%
+100,000
New +$3.97M
APTO
49
DELISTED
Aptose Biosciences, Inc.
APTO
$4.3M 0.26%
+2,180
New +$5.12M
IGMS
50
DELISTED
IGM Biosciences
IGMS
$3.98M 0.24%
+45,131
New +$3.17M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2020 Portfolio in Review

As of Q4 2020, Sofinnova Investments held 89 positions worth $1.68B, up 25% from $1.35B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sofinnova Investments deployed $76.5M of net new capital in Q4 2020, opening 21 new positions and adding to 18 existing holdings. Its largest new stake was AstraZeneca: 421,300 shares worth $42.1M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier.

On the sell side, the largest reduction was Eli Lilly, an estimated $15.8M trimmed.

  • Sofinnova Investments's largest Q4 2020 buy was AstraZeneca: 421,300 shares worth $42.1M.
  • Sofinnova Investments added most to Jazz Pharmaceuticals in Q4 2020, an estimated $12.3M increase.
  • Sofinnova Investments's biggest Q4 2020 reduction was Eli Lilly, cutting an estimated $15.8M.
  • Sofinnova Investments fully exited NextCure in Q4 2020, selling an estimated $23.5M.
  • Sofinnova Investments's ten largest holdings make up 63% of its $1.68B portfolio in Q4 2020.
  • Sofinnova Investments opened 21 new positions and closed 21 in Q4 2020.
  • Sofinnova Investments's portfolio value rose 25% quarter-over-quarter to $1.68B.

Based on Sofinnova Investments's 13F filing for Q4 2020, filed 16 Feb 2021.